Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Recruiting

Testing Bisoprolol in Patients with Acute or Recurrent Pericarditis to Reduce Symptoms and Prevent Recurrence

Verified siteRegistered drugNo placebo
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This study is looking at pericarditis, which is a condition where the tissue surrounding the heart becomes inflamed. Pericarditis can occur for the first time (acute) or can come back after treatment (recurrent). The medication being tested in this study is bisoprolol, which belongs to a group of medicines called beta-blockers that work by slowing down the heart rate and reducing the workload on the heart.

The purpose of this study is to find out if bisoprolol can help reduce symptoms of pericarditis and prevent the condition from coming back. The study will look at whether the treatment helps symptoms go away within two and four weeks, and whether it lowers the chances of the condition returning within twelve months. Participants will receive bisoprolol at a dose of 1.25 milligrams daily, taken by mouth, for a period of up to 28 days.

During the study, patients will be monitored to see how their symptoms change over time. The study will track whether chest pain and other symptoms continue at different time points, including at one, two, and four weeks. The study will also follow participants for twelve months to see if pericarditis comes back. Additionally, the study will examine the relationship between certain blood test results that show inflammation and heart rate measurements taken at the beginning of the study.

The research process

The trial runs in 4 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Initial enrollment and treatment start

    Upon joining the study, treatment will begin within 48 hours of the onset of symptoms related to pericarditis (inflammation of the tissue surrounding the heart).

    The study medication is bisoprolol, which belongs to a group of medicines called beta-blockers that help reduce heart rate and workload on the heart.

    The medication will be taken by mouth (oral use).

    The specific dosage and frequency of bisoprolol administration have not been detailed in the available information.

  2. Step 2

    First follow-up assessment

    At 2 weeks after starting treatment, an assessment will be conducted to evaluate whether symptoms of pericarditis are still present.

    This evaluation will help determine how well the treatment is working in reducing symptoms.

  3. Step 3

    Second follow-up assessment

    At 4 weeks (1 month) after starting treatment, another assessment will be performed.

    This visit will check for the persistence of symptoms and monitor the response to the medication.

  4. Step 4

    Long-term monitoring period

    Monitoring will continue for up to 12 months after starting treatment.

    During this period, assessments will focus on identifying any recurrence (relapse) of pericarditis symptoms.

    The frequency of relapses will be tracked throughout this 12-month period.

Who can join the trial?

6 criteria

  • You must have acute pericarditis, which is a sudden inflammation of the tissue surrounding the heart, or recurrent pericarditis, which means the inflammation has come back after a previous episode. The cause of the inflammation can be any reason.
  • Your symptoms must have started within the last 48 hours, meaning two days or less.
  • You must be at least 18 years old or older.
  • You must be able to provide informed consent, which means you understand the study and agree to take part in it.
  • You must be willing to follow all the procedures required by the study.
  • Both men and women can participate in this study.

Who cannot join the trial?

3 criteria

  • The source data does not provide specific exclusion criteria (reasons why patients cannot participate) for this clinical trial
  • Without detailed exclusion criteria listed in the trial information, it is not possible to identify specific conditions, medications, or situations that would prevent participation
  • Typically, clinical trials have exclusion criteria such as certain medical conditions, medications being taken, allergies, pregnancy status, or other factors, but these are not specified in the available information
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

Bisoprolol is a medication that belongs to a group of medicines called beta-blockers. It works by slowing down the heart rate and reducing the force with which the heart pumps blood. In this trial, bisoprolol is being tested to see if it can help reduce symptoms of pericarditis (inflammation of the tissue surrounding the heart) and prevent the condition from coming back.

What is already known about the treatment

Bisoprolol – Bisoprolol is a medication that belongs to a group of drugs called beta-blockers, which work by slowing down the heart rate and reducing the force of heart contractions by blocking specific receptors in the heart muscle. It is commonly used to treat high blood pressure, heart failure, and irregular heartbeats, and is typically taken as a tablet by mouth once daily. In this clinical trial, researchers are studying whether bisoprolol can help reduce symptoms and prevent recurrence in patients suffering from pericarditis, which is an inflammation of the protective sac surrounding the heart. This represents a new potential use for bisoprolol that is currently being investigated through research.

Investigated diseases

Pericarditis – Pericarditis is an inflammation of the pericardium, which is the thin, two-layered, fluid-filled sac that surrounds the heart. The condition causes chest pain that may feel sharp or stabbing, and it often worsens when breathing deeply or lying down. The inflammation can develop suddenly and may be accompanied by fever and a general feeling of being unwell. In some cases, fluid can accumulate between the layers of the pericardium, putting pressure on the heart. The condition may resolve after a few weeks, but some people experience recurring episodes where the inflammation returns. Symptoms typically include chest discomfort, difficulty breathing, and sometimes a rapid heartbeat.
Trial detailsLast updated 2 Oct 2026
Age18+ yearsPhasePhase IIITrial ID2025-523015-11-00Protocol codeBIPEstimated enrolment300 patientsSponsorAzienda Sanitaria Universitaria Friuli Centrale

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.